申请人:SNU R & DB Foundation
公开号:EP2615094A2
公开(公告)日:2013-07-17
The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed.
本发明涉及酯萜类化合物、其在活体内可水解的前体或其药学上可接受的盐,还涉及酯萜类化合物对非胰岛素依赖型糖尿病的预防和治疗效果、糖尿病并发症(由糖尿病引起的肾功能衰竭和足部溃疡)、酒精性、非酒精性和病毒性脂肪肝、肥胖症、高脂血症、动脉粥样硬化、心血管疾病(如动脉粥样硬化性中风)和脑病(帕金森病、精神分裂症和阿尔茨海默病)。此外,本发明还涉及用于功能性食品、功能性饮料、功能性化妆品和功能性饲料的组合物。